nach oben

Acta Neurologica Belgica

Erschienen in:

04.07.2016 | Original Article

Glucose-6-phosphate dehydrogenase a novel hope on a blood-based diagnosis of Alzheimer’s disease

verfasst von: Ahmet Evlice, Nuriye Nuray Ulusu

Erschienen in: Acta Neurologica Belgica | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Alzheimer’s disease (AD) is a multi-factorial neurodegenerative disorder that numerous factors have key properties in the development of this proteopathy. Glucose-6-phosphate dehydrogenase (G6PD) is the most common form of enzymopathy. We have examined G6PD enzyme activity levels in the serum of newly diagnosed AD patients compared with control subjects without dementia from the both sexes. Serum G6PD levels were found to be significantly higher (approximately two times) in AD patients compared to control geriatric subjects in both sexes. We have concluded that G6PD seems to play an integral role in the progress and/or prevention of AD.

Tran L, Ha-Duong T (2015) Exploring the Alzheimer amyloid-β peptide conformational ensemble: a review of molecular dynamics approaches. Peptides 20:86–91. doi:10.1016/j.peptides.2015.04.009 (Epub 2015 Apr 20) CrossRef

Arevalo-Rodriguez I, Smailagic N, Roqué I Figuls M, Ciapponi A, Sanchez-Perez E, Giannakou A, Pedraza OL, BonfillCosp X, Cullum S (2015) Mini-Mental State Examination (MMSE) for the detection of Alzheimer’s disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 5(3):CD010783. doi:10.1002/14651858.CD010783.pub2

McGovern J (2015) Living better with dementia: strengths-based social work practice and dementia care. Soc Work Health Care 54:408–421. doi:10.1080/00981389.2015.1029661 CrossRefPubMed

Gregori M, Masserini M, Mancini S (2015) Nanomedicine for the treatment of Alzheimer’s disease. Nanomedicine (London) 10:1203–1218. doi:10.2217/nnm.14.206 CrossRef

Deacon RM, Altimiras FJ, Bazan-Leon EA, Pyarasani RD, Nachtigall FM, Santos LS, Tsolaki AG, Pednekar L, Kishore U, Biekofsky RR, Vasquez RA, Cogram P (2015) Natural AD-like neuropathology in octodon degus: impaired burrowing and neuroinflammation. Curr Alzheimer Res 12:314–322CrossRefPubMed

Jaworski T, Dewachter I, Seymour CM, Borghgraef P, Devijver H, Kügler S, Van Leuven F (2010) Alzheimer’s disease: old problem, new views from transgenic and viral models. Biochim Biophys Acta 1802:808–818. doi:10.1016/j.bbadis.2010.03.005 (Epub 2010 Mar 21) CrossRefPubMed

Mayeux R, Schupf N (2011) Blood-based biomarkers for Alzheimer’s disease: plasma Abeta40 and Abeta42, and genetic variants. Neurobiol Aging 32:10–19. doi:10.1016/j.neurobiolaging09.004 CrossRef

Thambisetty M, Lovestone S (2010) Blood-based biomarkers of Alzheimer’s disease: challenging but feasible. Biomark Med 4:65–79CrossRefPubMedPubMedCentral

Erickson MA, Banks WA (2013) Blood–brain barrier dysfunction as a cause and consequence of Alzheimer’s disease. J Cereb Blood Flow Metab 33:1500–1513. doi:10.1038/jcbfm.2013.135 (Epub 2013 Aug 7) CrossRefPubMedPubMedCentral

10.

Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, Vitek MP, Hovanesian V, Stopa EG (2007) Microvascular injury and blood–brain barrier leakage in Alzheimer’s disease. Neurobiol Aging 28:977–986CrossRefPubMed

11.

Lewczuk P, Kornhuber J (2011) Neurochemical dementia diagnostics in Alzheimer’s disease: where are we now and where are we going? Expert Rev Proteom 8:447–458. doi:10.1586/EPR.11.37 CrossRef

12.

Huang Y, Mahley RW (2014) Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer’s diseases. Neurobiol Dis 72:3–12. doi:10.1016/j.nbd.2014.08.025 (Epub 2014 Aug 27) CrossRefPubMed

13.

Revel F, Gilbert T, Roche S, Drai J, Blond E, Ecochard R, Bonnefoy M (2015) Influence of oxidative stress biomarkers on cognitive decline. J Alzheimers Dis 45:553–560. doi:10.3233/JAD-141797 PubMed

14.

Ulusu NN, Yilmaz G, Erbayraktar Z, Evlice A, Aras S, Yener G, Avcı A (2015) A Turkish three-center study evaluation of serum folic acid and vitamin B12 levels in Alzheimer`s disease. Turk J Med Sci 45:1159–1166. doi:10.3906/sag-1406-136 CrossRefPubMed

15.

Ulusu NN, Yılmaz G, Erbayraktar Z, Evlice A, Genç M, Aras S, Avcı A, Yener G (2015) A comparative study on thyroid function in Alzheimer’s disease: results from a Turkish multi-center study. J NeurolSci (Turk) 32:335–347

16.

Wiltfang J (2015) Novel methods for dementia diagnostics. Nervenarzt 86:452–460. doi:10.1007/s00115-014-4177-5 CrossRefPubMed

17.

Mäkelä KM, Traylor M, Oksala N, Kleber ME, Seppälä I, Lyytikäinen LP, Hernesniemi JA, Kähönen M, Bevan S, Rothwell PM, Sudlow C, Dichgans M, Wellcome Trust Case Control Consortium 2 (WTCCC2), Delgado G, Grammer TB, Scharnagl H, Markus HS, März W, Lehtimäki T (2014) Association of the novel single-nucleotide polymorphism which increases oxidized low-density lipoprotein levels with cerebrovascular disease events. Atherosclerosis. 234:214–217. doi:10.1016/j.atherosclerosis.2014.03.002 (Epub 2014 Mar 14) CrossRefPubMed

18.

Phompradit P, Kuesap J, Chaijaroenkul W, Rueangweerayut R, Hongkaew Y, Yamnuan R, Na-Bangchang K (2011) Prevalence and distribution of glucose-6-phosphate dehydrogenase (G6PD) variants in Thai and Burmese populations in malaria endemic areas of Thailand. Malar J 15:1–8. doi:10.1186/1475-2875-10-368

19.

Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, Hogg MM, Battle KE, Padilla CD, Baird JK, Hay SI (2012) G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med 9:e1001339. doi:10.1371/journal.pmed.1001339 (Epub 2012 Nov 13) CrossRefPubMedPubMedCentral

20.

WHO (1989) Glucose-6-phosphate dehydrogenase deficiency. WHO working group. Bull World Health Organ 67:601–611

21.

Morrison BF, Thompson EB, Shah SD, Wharfe GH (2014) Ischaemic priapism and glucose-6-phosphate dehydrogenase deficiency: a mechanism of increased oxidative stress? West Indian Med J63:658–660. doi:10.7727/wimj.2013.294 (Epub 2014 Aug 21)

22.

Ahmad A, Khan MM, Javed H, Raza SS, Ishrat T, Khan MB, Safhi MM, Islam F (2012) Edaravone ameliorates oxidative stress associated cholinergic dysfunction and limits apoptotic response following focal cerebral ischemia in rat. Mol Cell Biochem 367:215–225. doi:10.1007/s11010-012-1335-6 (Epub 2012 May 22) CrossRefPubMed

23.

Ulusu NN, Tandogan B, Tezcan FE (2005) Kinetic properties of glucose-6-phosphate dehydrogenase from lamb kidney cortex. Biochimie 87:187–190CrossRefPubMed

24.

Ulusu NN, Tandogan B (2006) Purification and kinetics of sheep kidney cortex glucose-6-phosphate dehydrogenase. Comp Biochem Physiol B Biochem Mol Biol 143:249–255CrossRefPubMed

25.

Laske C, Sohrabi HR, Frost SM, López-de-Ipiña K, Garrard P, Buscema M, Dauwels J, Soekadar SR, Mueller S, Linnemann C, Bridenbaugh SA, Kanagasingam Y, Martins RN, O’Bryant SE (2015) Innovative diagnostic tools for early detection of Alzheimer’s disease. Alzheimers Dement 11:561–578. doi:10.1016/j.jalz.2014.06.004 (Epub 2014 Nov 15) CrossRefPubMed

26.

Henriksen K, O’Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A, Blennow K, Lönneborg A, Wyss-Coray T, Soares H, Bazenet C, Sjögren M, Hu W, Lovestone S, Karsdal MA, Weiner MW, Blood-Based Biomarker Interest Group (2014) The future of blood-based biomarkers for Alzheimer’s disease. Alzheimers Dement 10:115–131. doi:10.1016/j.jalz.2013.01.013 (Epub 2013 Jul 11) CrossRefPubMed

27.

Korolainen MA, Nyman TA, Aittokallio T, Pirttilä T (2010) An update on clinical proteomics in Alzheimer’s research. J Neurochem 112:1386–1414. doi:10.1111/j.1471-4159.2009.06558.x (Epub 2009 Dec 24) CrossRefPubMed

28.

Siesjö BK (1981) Cell damage in the brain: a speculative synthesis. J Cereb Blood Flow Metab 1:155–185CrossRefPubMed

29.

Russell RL, Siedlak SL, Raina AK, Bautista JM, Smith MA, Perry G (1999) Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease. Arch Biochem Biophys 15:236–239CrossRef

30.

Martins RN, Harper CG, Stokes GB, Masters CL (1986) Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer’s disease may reflect oxidative stress. J Neurochem 46:1042–1045CrossRefPubMed

31.

Ulusu NN (2015) Glucose-6-phosphate dehydrogenase deficiency and Alzheimer’s disease: partners in crime? The hypothesis. Med Hypotheses 85:219–223. doi:10.1016/j.mehy.2015.05.006 (Epub 2015 May 11) CrossRefPubMed

32.

Levonen AL, Hill BG, Kansanen E, Zhang J, Darley-Usmar VM (2014) Redox regulation of antioxidants, autophagy, and the response to stress: implications for electrophile therapeutics. Free Radic Biol Med 71:196–207. doi:10.1016/j.freeradbiomed.2014.03.025 (Epub 2014 Mar 26) CrossRefPubMedPubMedCentral

33.

Kim J, Devalaraja-Narashimha K, Padanilam BJ (2015) TIGAR regulates glycolysis in ischemic kidney proximal tubules. Am J Physiol Renal Physiol 15:298–308. doi:10.1152/ajprenal.00459.2014 (Epub 2014 Dec 10) CrossRef

34.

Parthasarathy S, Yoo B, McElheny D, Tay W, Ishii Y (2014) Capturing a reactive state of amyloid aggregates: NMR-based characterization of copper-bound Alzheimer disease amyloid β-fibrils in a redox cycle. J Biol Chem 289:9998–10010. doi:10.1074/jbc.M113.511345 (Epub 2014 Feb 12) CrossRefPubMedPubMedCentral

35.

Jeng W, Loniewska MM, Wells PG (2013) Brain glucose-6-phosphate dehydrogenase protects against endogenous oxidative DNA damage and neurodegeneration in aged mice. ACS Chem Neurosci J 17:1123–1132. doi:10.1021/cn400079y (Epub 2013 May 14) CrossRef

36.

Paik SR, Lee D, Cho HJ, Lee EN, Chang CS (2003) Oxidized glutathione stimulated the amyloid formation of alpha-synuclein. FEBS Lett 27(537):63–67. doi:10.1016/S0014-5793(03)00081-4 (Epub 29 Jan 2003) CrossRef

Titel: Glucose-6-phosphate dehydrogenase a novel hope on a blood-based diagnosis of Alzheimer’s disease
verfasst von: Ahmet Evlice
Nuriye Nuray Ulusu
Publikationsdatum: 04.07.2016
Verlag: Springer International Publishing
Erschienen in: Acta Neurologica Belgica / Ausgabe 1/2017
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI: https://doi.org/10.1007/s13760-016-0666-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Glucose-6-phosphate dehydrogenase a novel hope on a blood-based diagnosis of Alzheimer’s disease

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Malignant transformation of low-grade gliomas in patients undergoing adjuvant therapy

Pseudotumoral brain lesions: MRI review

Acute dystonic reaction in a patient with Parkinson’s disease after diphenhydramine withdrawal

Pupil cycle time: as indicator of visual pathway dysfunction in multiple sclerosis

Associations between MDR1 C3435T polymorphism and drug-resistant epilepsy in the Polish population

Treatment of Wallenberg’s Syndrome related dysphagia with pyridostigmine

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie